Capricor Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded no revenue for the second quarter of 2025, a decrease from $3.97 million in the same period of 2024. For the first half of 2025, total revenue also fell to zero, down from $8.88 million in the first half of 2024. The absence of revenue was attributed to the completion of milestone payments from its collaboration with Nippon Shinyaku, which had previously contributed to revenue recognition.
Operating expenses for the second quarter of 2025 totaled approximately $27.72 million, a substantial increase from $15.56 million in the prior year, driven primarily by a 76% rise in research and development costs, which reached $22.05 million. This increase was largely due to heightened clinical trial activities and expanded manufacturing efforts for its lead product candidate, deramiocel, aimed at treating Duchenne muscular dystrophy (DMD). The company reported a net loss of $25.91 million for the quarter, compared to a loss of $10.99 million in the same quarter of 2024.
Capricor's total assets as of June 30, 2025, were approximately $133.57 million, a decrease from $170.48 million at the end of 2024. The decline in assets was primarily due to a reduction in marketable securities, which fell to $99.56 million from $140.23 million. The company’s cash and cash equivalents increased to $23.24 million, up from $11.29 million at the end of 2024, reflecting a net increase in cash flow from investing activities, which provided approximately $38.44 million during the first half of 2025.
Strategically, Capricor has been focused on advancing its clinical programs, particularly the ongoing Phase 3 HOPE-3 trial for deramiocel. The company has also entered into various commercialization and distribution agreements with Nippon Shinyaku for the U.S. and Japan, which include potential milestone payments totaling up to $80 million upon regulatory approval. The company is actively preparing a response to a Complete Response Letter (CRL) received from the FDA regarding its Biologics License Application (BLA) for deramiocel, which highlighted the need for additional clinical data.
Looking ahead, Capricor anticipates continued operational losses as it invests heavily in research and development. The company has indicated that it will require substantial additional capital to fund its ongoing operations and clinical trials. As of June 30, 2025, Capricor's accumulated deficit stood at approximately $250.14 million, underscoring the financial challenges it faces as it seeks to bring its product candidates to market. The company plans to finance its operations through a combination of equity and debt financing, as well as potential licensing agreements.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapies, primarily focusing on deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. Its proprietary platforms target muscle degeneration and inflammation through immunomodulatory and regenerative mechanisms. Capricor’s business model centers on advancing clinical development, manufacturing, and partnering for commercialization in key markets including the U.S. and Japan.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.